Streetbeat News

Analyst Ratings

CNK

Cinemark's stock is trading lower after B. Riley Securities downgraded it from Buy to Neutral.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2023 | 4:45 pm

INTU

MAXN

SSNLF

Maxeon Solar Technologies' shares climbed after signing a deal with Samsung Electronics. Roth MKM predicts margin expansion in 2023 and profitability in 2024 for Maxeon. Analyst Philip Shen upgraded Maxeon's rating to Buy and raised the price target from $21 to $40.

Portfolio Pulse from Priya Nigam

June 14, 2023 | 4:38 pm

LOGI

Citigroup analyst Asiya Merchant downgraded Logitech International (NASDAQ:LOGI) from Buy to Neutral and lowered the price target from $73 to $70.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2023 | 4:35 pm

CFLT

Confluent shares are trading lower after Guggenheim downgraded the stock from Buy to Neutral.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2023 | 4:30 pm

ONTX

HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Onconova Therapeutics (NASDAQ:ONTX) and maintains an $11 price target.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2023 | 4:23 pm

THC

Jefferies analyst Brian Tanquilut has reiterated a Buy rating on Tenet Healthcare (NYSE:THC) and maintained a $95 price target.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2023 | 4:15 pm

MTB

DA Davidson analyst Peter Winter maintains a Neutral rating on M&T Bank (NYSE:MTB) and lowers the price target from $138 to $132.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2023 | 4:13 pm

UNH

SVB Securities analyst Whit Mayo maintains an Outperform rating on UnitedHealth Group (NYSE:UNH) but lowers the price target from $625 to $560.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2023 | 4:10 pm

DOCS

PACB

VEEV

Arelis Agosto, a research analyst at Global X ETFs, sees investment opportunities in health-care companies leveraging AI technology. She recommends Pacific Bioscience of California (PACB), Veeva (VEEV), and Doximity (DOCS) as AI's application to the health-care space is still in its infancy.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2023 | 4:08 pm

NFLX

Wolfe Research analyst Peter Supino reiterates an Outperform rating on Netflix (NASDAQ:NFLX) and raises the price target from $388 to $485.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2023 | 4:07 pm